Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
FTSE 250 pharmaceutical group HIkma is to buy the Egyptian Company for Pharmaceuticals & Chemical Industries as it strengthens its position in a rapidly growing market. It is to pay EGP142.4m - around $22.2m - to buy the firm from a consortium of shareholders. Hikma's Chief Executive, Said Darwaz
Read moreHikma Pharmaceuticals announced Thursday the US launch of an injection for the treatment of thrombosis in adults. The FSTE 250 multinational group is releasing the argatroban injection after receiving approval from the US Food and Drug Administration earlier this year. The London-based pharmace
Read more- Markets gear up for climax of presidential race - Economic data disappoints - Corporate earnings impress, Resolution leads risers after upgrade The UK stock market shrugged off some disappointing economic data to finish Tuesday's session with decent gains as a barrage of updates and results from
Read moreHikma Pharmaceuticals got a boost after Panmure Gordon upgraded the stock from hold to buy and lifted its price target from 720p to 825p. Jefferies kept its buy rating on the stock and retained a 890p target. Recycled packing firm DS Smith said it continue to expect substantial year-on-year EPS gr
Read moreAB Foods: Jefferies keeps hold rating and 1,365p target; Panmure Gordon ups target from 1,300p to 1,450p, hold rating kept; Investec keeps hold rating and 1,300p target. Aviva: Panmure Gordon maintains buy rating and 425p target. Babcock: Jefferies keeps buy rating and 970p target; Seymour Pierce
Read more- US jobs provide temporary boost, but gains trimmed - Data unlikely to change Fed's stance, says analyst - Financials Admiral and RBS disappoint While the closely-watched US jobs report provided a bit of a bounce in early afternoon trade, the Footsie had pared gains to finish flat by the close as
Read moreMining group Bumi advanced after saying it has appointed Rothschild Goup as its financial adviser with immediate effect to evaluate the proposal received from Long Haul Holdings. Shares in Dixons rose once again, boosted by the news that its main High Street rival, Comet, is likely to go into admi
Read more- All eyes on US jobs data - Outcome could be a major factor in presidential elections - Admiral, Meggitt and RBS disappoint The FTSE 100 was little changed by Friday lunchtime, having trade within a narrow range for most of the morning session, with investors nervous ahead the pivotal employment
Read moreHikma Pharmaceuticals is considering the future of its Generics business as its Eatontown facility in New Jersey continues to be dogged by compliance issues. The group has opted to halt commercial production of generic drugs at Eatontown facility in the US until mid-January while it gets to grips
Read moreAfrican Barrick Gold: Investec raises target from 485p to 530p, hold rating kept. Aggreko: Seymour Pierce maintains buy rating and 2,500p target. AstraZeneca: Panmure Gordon keeps hold rating and 3,000p target. British American Tobacco: Jefferies keeps buy rating and 3,730p target; Panmure Gordon
Read moreShares in part-nationalised lender Royal Bank of Scotland (RBS) are trading at 0.6 times tangible net asset value (tNAV) and close to a new 17-month high, which has prompted broker Investec to downgrade its rating for the stock from 'hold' to 'sell'. Investec forecasts another "jaw-dropping statuto
Read moreUBS has cut its recommendation for pharmaceuticals group Hikma from 'neutral' to 'sell', saying that the market is pricing in a 'blue sky scenario'. The broker said that it is hard to justify Hikma's valuation "as we believe that the market is pricing a blue sky scenario with the US Injectables sup
Read moreFTSE 250 group Hikma Pharmaceuticals has signed an agreement for the registration and marketing of Lutrate 1 month, GP Pharm's anti-cancer compound, for the Middle East and North Africa (MENA) region. Lutrate 1 month is a hormonal androgen deprivation therapy used to prevent tumor growth in patien
Read more888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl
Read more- Stocks look to Jackson Hole summit for a boost - Draghi hints at action ahead of ECB meeting - Glencore leads fallers on growing opposition to merger Global stock markets were mostly trading in the red on Wednesday afternoon in spite an upwards revision to US economic growth as investors showed c
Read more
Last checked at